FDA
-
-
-
-
-
-
-
FDA Accepts New Drug Application for Genentech’s Giredestrant in ESR1-Mutated, ER-Positive Advanced Breast Cancer
-
-
-
-
-
-
-
Genentech Presents Lunsumio Data Showing Potential Across Earlier Treatment Lines in Indolent and Aggressive Lymphomas
-
-
-
-
-
-
-
FDA Approves Genentech’s Gazyva for the Treatment of Lupus Nephritis
-
-
-
-
-
-
-
Genentech Presents New Data for Ocrevus and Fenebrutinib Across Broad Patient Populations at ECTRIMS 2025
-
-
-
-
-
-
-
FDA rejects Genentech's Columvi combination for lymphoma treatment
-
-
-
-
-
-
-
Genentech’s Fenebrutinib Maintains Near-Complete Suppression of Disease Activity and Disability Progression for up to Two Years in People With Relapsing Multiple Sclerosis
-
-
-
-
-
-
-
Quest Diagnostics (DGX) Introduces HPV Specimen Self-Collection for Cervical Cancer Screening
-
322,933 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

